Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

Study now open for enrollment at leading academic medical centers CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today...

Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress

Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress

CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA),...

HKSH Medical Group to Host Hong Kong's First Asia-Oceania Particle Therapy Co-operative Group Conference

HKSH Medical Group to Host Hong Kong's First Asia-Oceania Particle Therapy Co-operative Group Conference

Best Practice by World-class Experts in Proton Therapy Transforming Precision Cancer Management HONG KONG, Oct. 21, 2025 /PRNewswire/ -- HKSH Medical Group (HKSH) introduced Hong Kong's only and the Greater Bay Area's first proton therapy system in...

menu
menu